Omeros Corp (OMER)

$11.38 -0.17 (-1.47%)
Market Cap 818.90M
Revenue (ttm) 0.00
Net Income (ttm) -156.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.80
Volume 687,600
Avg Vol 2,582,448
Day's Range N/A - N/A
Shares Out 70.90M
Stochastic %K 24%
Beta 2.44
Analysts Sell
Price Target $43.67

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 676 5000
Address:
The Omeros Building, 201 Elliott Avenue West, Seattle, United States
MarcJ55
MarcJ55 Feb. 26 at 4:59 PM
$OMER
0 · Reply
MarcJ55
MarcJ55 Feb. 26 at 4:46 PM
$OMER https://en.frontierbiotech.com/detail/251.html
1 · Reply
UltimoDaBaggie
UltimoDaBaggie Feb. 26 at 3:06 PM
$OMER TA-TMA is not a disease but a syndrome that can arise due to different reasons after a transplant. Ta-TMA mortality varies based on underlying reason, transplant and patient characteristics. It is actually OMER that established this diagnosis among medical community. Treatment for it varied between centers and there wasn’t a standard. Now we have a standard but every center will use it differently. Memorial BMT chief’s comments were unbelievably bullish for OMER. He stated that he would continue tacrolimus (most commonly used GVHD med and likely the most common reason for TA-TMA) and add narso for pts who develop TA-TMA on tacrolimus. Previously, one would stop tacrolimus which would increase GVHD risk. Memorial Sloan is no 2 BMT center in US by transplant numbers. So that is huge. However, I have not seen any docs from MD anderson in narso trials. I was not expecting such a product label for narso from FDA. I believe OMER is severely undervalued.
1 · Reply
resq1
resq1 Feb. 26 at 2:18 PM
$OMER am I the crazy one? I worked in banking, and buy side. I'm at the point that I'm questioning if "transplant-associated thrombotic microangiopathy (TA-TMA)" is an real thing. Like... That's what this price action makes me feel like. Maybe I'm dumb for believing it's a disease. Maybe I'm gullible, as I thankfully don't know anyone who has suffered it. Meanwhile I'm shocked at price action even playing under 1.5bn mkt cap
1 · Reply
tyrus6
tyrus6 Feb. 26 at 1:18 PM
$OMER from Tradingview .com
0 · Reply
vu_jade
vu_jade Feb. 26 at 1:04 PM
$OMER approved drug .. just getting started
0 · Reply
naturegirl669
naturegirl669 Feb. 26 at 7:32 AM
$OMER - Did they forget about YART?? "Key details regarding Omeros' profitability outlook: Forecasted Timeline: While some estimates expect a final loss in 2025 followed by profit in 2026, other projections suggest a final loss in 2026 with profitability arriving in 2027. Key Drivers: Profitability is driven by revenue from OMIDRIA royalties and potential payments from the licensing deal for zaltenibart with Novo Nordisk. Analyst Projections: Analysts are optimistic, anticipating an average annual growth rate of 71% to 77% to meet these targets. Cash Runway: Omeros reported a cash runway extending through 2027, largely aided by recent licensing deals. The company is in a, high-stakes phase, and profitability depends heavily on the successful commercialization and development of its pipeline."
3 · Reply
DragonAlgo
DragonAlgo Feb. 26 at 7:10 AM
🐉 $OMER CALL — DragonAlgo® Signal Contract: OMER CALL Expiry: 2026-03-20 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.45 Stop: $0.32 TP1: $0.59 TP2: $0.77 TP3: $1.08 🔗 https://dragonalgo.com
0 · Reply
Holdyn_Baggins
Holdyn_Baggins Feb. 26 at 1:15 AM
$OMER gotta get things moving here. I know a guy…
0 · Reply
mjk49
mjk49 Feb. 26 at 12:12 AM
$OMER MM games until we hear from Greg on sales outlook next ER call.
1 · Reply
Latest News on OMER
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Feb 17, 2026, 8:45 AM EST - 9 days ago

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Omeros Announces First Commercial Sales of YARTEMLEA®

Jan 27, 2026, 9:00 AM EST - 4 weeks ago

Omeros Announces First Commercial Sales of YARTEMLEA®

Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript

Jan 7, 2026, 9:07 PM EST - 7 weeks ago

Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript

Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 6:50 PM EST - 7 weeks ago

Omeros prices transplant complication drug at $36,000 per dose

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Dec 26, 2025, 6:36 PM EST - 2 months ago

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely

Dec 24, 2025, 2:14 PM EST - 2 months ago

Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely

Gold Edges Lower; Omeros Shares Jump

Dec 24, 2025, 12:21 PM EST - 2 months ago

Gold Edges Lower; Omeros Shares Jump

AAAU BAR DBP GLD GLDM IAU OUNZ

US FDA approves Omeros' drug to treat dangerous transplant complication

Dec 24, 2025, 9:05 AM EST - 2 months ago

US FDA approves Omeros' drug to treat dangerous transplant complication

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Dec 24, 2025, 9:00 AM EST - 2 months ago

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Dec 1, 2025, 8:30 AM EST - 3 months ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript

Nov 17, 2025, 10:37 AM EST - 3 months ago

Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript

Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 4:11 PM EST - 3 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Nov 11, 2025, 8:30 AM EST - 3 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting

Oct 17, 2025, 4:43 PM EDT - 4 months ago

Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting

Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case

Oct 16, 2025, 10:08 AM EDT - 4 months ago

Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case

NVO

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Oct 16, 2025, 8:30 AM EDT - 4 months ago

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Oct 15, 2025, 2:58 PM EDT - 4 months ago

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

NVO

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Oct 15, 2025, 11:54 AM EDT - 4 months ago

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

Oct 15, 2025, 9:17 AM EDT - 4 months ago

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

NVO

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

Oct 15, 2025, 8:32 AM EDT - 4 months ago

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

NVO

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Oct 15, 2025, 8:30 AM EDT - 4 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Sep 2, 2025, 8:45 AM EDT - 6 months ago

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 4:41 PM EDT - 6 months ago

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:02 PM EDT - 6 months ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Aug 11, 2025, 4:02 PM EDT - 7 months ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jul 25, 2025, 8:00 AM EDT - 7 months ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Jun 27, 2025, 8:30 AM EDT - 8 months ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Jun 24, 2025, 8:30 AM EDT - 8 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Jun 10, 2025, 12:53 PM EDT - 9 months ago

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

May 27, 2025, 11:12 PM EDT - 9 months ago

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 9:07 PM EDT - 10 months ago

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

Omeros Corporation Reports First Quarter 2025 Financial Results

May 15, 2025, 4:05 PM EDT - 10 months ago

Omeros Corporation Reports First Quarter 2025 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 5:05 PM EDT - 10 months ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 12, 2025, 10:35 AM EDT - 10 months ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

May 6, 2025, 9:16 AM EDT - 10 months ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 11, 2025, 3:06 PM EDT - 11 months ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 10, 2025, 9:10 AM EDT - 11 months ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Apr 8, 2025, 9:00 AM EDT - 11 months ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 8:57 PM EDT - 11 months ago

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 31, 2025, 4:02 PM EDT - 11 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Mar 28, 2025, 7:39 AM EDT - 11 months ago

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 26, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Mar 21, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Feb 24, 2025, 4:44 PM EST - 1 year ago

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 20, 2025, 9:10 AM EST - 1 year ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 14, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Feb 10, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Jan 16, 2025, 9:15 AM EST - 1 year ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Dec 19, 2024, 12:28 PM EST - 1 year ago

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 19, 2024, 9:15 AM EST - 1 year ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

MarcJ55
MarcJ55 Feb. 26 at 4:59 PM
$OMER
0 · Reply
MarcJ55
MarcJ55 Feb. 26 at 4:46 PM
$OMER https://en.frontierbiotech.com/detail/251.html
1 · Reply
UltimoDaBaggie
UltimoDaBaggie Feb. 26 at 3:06 PM
$OMER TA-TMA is not a disease but a syndrome that can arise due to different reasons after a transplant. Ta-TMA mortality varies based on underlying reason, transplant and patient characteristics. It is actually OMER that established this diagnosis among medical community. Treatment for it varied between centers and there wasn’t a standard. Now we have a standard but every center will use it differently. Memorial BMT chief’s comments were unbelievably bullish for OMER. He stated that he would continue tacrolimus (most commonly used GVHD med and likely the most common reason for TA-TMA) and add narso for pts who develop TA-TMA on tacrolimus. Previously, one would stop tacrolimus which would increase GVHD risk. Memorial Sloan is no 2 BMT center in US by transplant numbers. So that is huge. However, I have not seen any docs from MD anderson in narso trials. I was not expecting such a product label for narso from FDA. I believe OMER is severely undervalued.
1 · Reply
resq1
resq1 Feb. 26 at 2:18 PM
$OMER am I the crazy one? I worked in banking, and buy side. I'm at the point that I'm questioning if "transplant-associated thrombotic microangiopathy (TA-TMA)" is an real thing. Like... That's what this price action makes me feel like. Maybe I'm dumb for believing it's a disease. Maybe I'm gullible, as I thankfully don't know anyone who has suffered it. Meanwhile I'm shocked at price action even playing under 1.5bn mkt cap
1 · Reply
tyrus6
tyrus6 Feb. 26 at 1:18 PM
$OMER from Tradingview .com
0 · Reply
vu_jade
vu_jade Feb. 26 at 1:04 PM
$OMER approved drug .. just getting started
0 · Reply
naturegirl669
naturegirl669 Feb. 26 at 7:32 AM
$OMER - Did they forget about YART?? "Key details regarding Omeros' profitability outlook: Forecasted Timeline: While some estimates expect a final loss in 2025 followed by profit in 2026, other projections suggest a final loss in 2026 with profitability arriving in 2027. Key Drivers: Profitability is driven by revenue from OMIDRIA royalties and potential payments from the licensing deal for zaltenibart with Novo Nordisk. Analyst Projections: Analysts are optimistic, anticipating an average annual growth rate of 71% to 77% to meet these targets. Cash Runway: Omeros reported a cash runway extending through 2027, largely aided by recent licensing deals. The company is in a, high-stakes phase, and profitability depends heavily on the successful commercialization and development of its pipeline."
3 · Reply
DragonAlgo
DragonAlgo Feb. 26 at 7:10 AM
🐉 $OMER CALL — DragonAlgo® Signal Contract: OMER CALL Expiry: 2026-03-20 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.45 Stop: $0.32 TP1: $0.59 TP2: $0.77 TP3: $1.08 🔗 https://dragonalgo.com
0 · Reply
Holdyn_Baggins
Holdyn_Baggins Feb. 26 at 1:15 AM
$OMER gotta get things moving here. I know a guy…
0 · Reply
mjk49
mjk49 Feb. 26 at 12:12 AM
$OMER MM games until we hear from Greg on sales outlook next ER call.
1 · Reply
jmmoore4
jmmoore4 Feb. 25 at 11:48 PM
$OMER Same old ish until BOOM! 💥
0 · Reply
hopeful2bright
hopeful2bright Feb. 25 at 10:53 PM
$OMER With roughly 24% short to COVER, EMA June(ish) approval, sales growing qtr over qtr, think power keg move up over say one year time period. My average is around $12 and in for 6 figures. Don’t look at it everyday, know what you own and be thankful for above. Unless the world ends which doesn’t matter for anything one may own, imo you will be very very happy with the returns here. Only thing that stops this is buyout or lack of sales but this saves lives and sales should increase qtr over qtr. God Bless. Didn’t think I would get in after approval but imo a GREAT INVESTMENT.
1 · Reply
MinnieSteve3
MinnieSteve3 Feb. 25 at 9:50 PM
$OMER Short interest at 2/13/2025 is 17,959,196 shares up 297,298 shares from 17,661,898 shares at 1/30/2025 and up 4,712.001 shares from 13,248,185 shares at 12/31/2025. https://www.nasdaq.com/market-activity/stocks/omer/short-interest
1 · Reply
WinstonWolfff
WinstonWolfff Feb. 25 at 9:11 PM
$OMER $OMER This is why we OG's are adding "value" shares here. A Schwab Growth Rating of B and a Valuation grade of F.
1 · Reply
Arad288
Arad288 Feb. 25 at 6:11 PM
$OMER add of you have powder
4 · Reply
mjk49
mjk49 Feb. 25 at 6:09 PM
$OMER It doesn’t go with the market… Need to wait until next ER call…
1 · Reply
resq1
resq1 Feb. 25 at 5:49 PM
$OMER time to add
0 · Reply
MinnieSteve3
MinnieSteve3 Feb. 25 at 3:17 PM
$OMER Funny and sad. Greg could probably sell Omeros tomorrow for $5 billion, and yet at the same time we struggle to maintain an $800 million market cap. What a racket.
2 · Reply
Holdyn_Baggins
Holdyn_Baggins Feb. 25 at 2:22 PM
$IBRX $ONDS $OMER $MAIN $BXMT
0 · Reply
UltimoDaBaggie
UltimoDaBaggie Feb. 25 at 12:53 PM
$OMER I read some about IBRX drug Anktiva. Their lung Ca results were were released as business wire. It looks total BS. My fellow omerites, I recommend you stay away from it
1 · Reply
DragonAlgo
DragonAlgo Feb. 25 at 12:40 PM
🐉 $OMER CALL — DragonAlgo® Signal Contract: OMER CALL Expiry: 2026-03-20 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.60 Stop: $0.43 TP1: $0.78 TP2: $1.02 TP3: $1.44 🔗 https://dragonalgo.com
0 · Reply
kreftslag
kreftslag Feb. 25 at 10:25 AM
$OMER maiby news on that one soon?
0 · Reply